BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
BCTXL Chart
BriaCell Therapeutics Corp. Warrant expiring 2031 Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 536,600 | $552,751.98 | $499,038.01 | -$53,713.97 | -9.72% |
| BO Brian Oliveira Clear Street Group Inc. | 104,196 | $107,332 | $96,902.28 | -$10,429.72 | -9.72% |
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BriaCell Therapeutics Corp. Warrant expiring 2031 ever had a stock split?
BriaCell Therapeutics Corp. Warrant expiring 2031 Profile
| Biotechnology Industry | Healthcare Sector | Dr. William V. Williams M.D. CEO | NASDAQ (NMS) Exchange | - ISIN |
| US Country | 16 Employees | - Last Dividend | - Last Split | 24 Feb 2021 IPO Date |
Overview
BriaCell Therapeutics Corp. stands out as a significant player in the biotechnology industry, particularly for its role in transforming cancer treatment through innovative cellular immunotherapies. Operating from West Vancouver, Canada, the company is actively engaged in a pivotal Phase 3 clinical trial geared towards addressing advanced breast cancer. This trial is particularly noteworthy for its investigation into the efficacy of Bria-IMT in combination with an immune checkpoint inhibitor, an approach that potentially paves the way for groundbreaking treatment modalities in cancer care. Moreover, BriaCell's collaborative efforts with Incyte Corporation to assess the combination of the Bria-IMT further underscores its commitment to innovation in the development of cancer therapies. The strategic focus on developing personalized off-the-shelf treatments not only for breast cancer but also for prostate cancer and other malignancies, showcases BriaCell’s versatility and its dedication to addressing a broad spectrum of oncological challenges through cutting-edge biotechnological advancements.
Products and Services
- Bria-IMT in Combination with an Immune Checkpoint Inhibitor
- Personalized Off-the-shelf Treatments for Breast Cancer, Prostate Cancer, and Other Cancers
This innovative treatment is currently in a pivotal Phase 3 clinical trial targeting advanced breast cancer. The Bria-IMT, when used in conjunction with an immune checkpoint inhibitor, represents BriaCell Therapeutics Corp.'s forefront offering in its arsenal of cellular immunotherapies. It is designed to enhance the immune system's response to cancer cells, potentially offering a significant advancement in the treatment of advanced breast cancer. This approach reflects the company's strategic emphasis on leveraging the body's immune system to fight cancer.
Understanding the unique genetic and immune profiles of each cancer patient stands at the core of BriaCell Therapeutics Corp.'s initiative to develop personalized treatments. These off-the-shelf treatments for breast cancer, prostate cancer, and other cancers signify a bold step towards more targeted and effective cancer care. The company's commitment to personalization reflects a broader industry trend towards tailor-made therapies, aiming to significantly improve clinical outcomes across various types of cancer.
